A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-06-09) →
What happened
Samsung Biologics updated a previously disclosed supply contract, now worth US$238M, about 7.7% of its recent annual revenue, running through Mar 2032.
For context, this single contract equals about 7.7% of the company's most recent annual revenue.
| Counterparty | Disclosed |
|---|---|
| Contract value | US$238M |
| vs. recent revenue | 7.7% |
| Through | Mar 2032 (from Jul 2025) |
| Filed | 2026-04-10, [Amended] Supply contract signed |
| Source | DART rcept 20260410800490 → open original filing |
Versions of this filing
- 2026-03-13Original
- 2026-04-10Amendment 1 (this page)
- 2026-06-09Amendment 2
Source: DART. Information only, not investment advice.